Intellia Therapeutics (NTLA) Current Assets (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Current Assets data on file, last reported at $466.4 million in Q1 2026.

• Current Assets for Q1 2026 came in at $466.4 million, down 15.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $466.4 million (down 15.41% YoY), and the FY2025 annual result was $527.7 million, down 17.53% from the prior year.
• Current Assets retreated to $466.4 million in Q1 2026 per NTLA's latest filing, from $527.7 million in the prior quarter.
• Over five years, Current Assets peaked at $1.2 billion in Q4 2022 and troughed at $466.4 million in Q1 2026.
• A 5-year average of $779.8 million and a median of $858.9 million in 2022 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2025: Current Assets jumped 62.98% in 2022, then slumped 37.63% in 2025.
• A 5-year view of Current Assets shows it stood at $1.2 billion in 2022, then slipped by 17.95% to $998.3 million in 2023, then tumbled by 35.91% to $639.9 million in 2024, then dropped by 17.53% to $527.7 million in 2025, then fell by 11.61% to $466.4 million in 2026.
• Business Quant data shows NTLA's Current Assets at $466.4 million in Q1 2026, $527.7 million in Q4 2025, and $581.9 million in Q3 2025.